Mark E. Hensley - 28 Apr 2025 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
Chief Operating Officer
Signature
/s/Kathryn Lester Attorney-in-fact for Mark E. Hensley
Issuer symbol
HRTX
Transactions as of
28 Apr 2025
Net transactions value
$0
Form type
4
Filing time
29 Apr 2025, 12:47:33 UTC
Next filing
07 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding HRTX Employee Stock Option (Right to Buy) 500,000 28 Apr 2025 Common Stock 500,000 $2.33 Direct F1
holding HRTX Employee Performance Stock Option (Right to Buy) 900,000 28 Apr 2025 Common Stock 900,000 $2.33 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable with respect to 125,000 shares on the first anniversary of the date of grant, followed by 375,000 shares vesting ratably each month over the subsequent three years, such that 500,000 options will be fully vested on the four year anniversary of the date of grant.
F2 The stock option vests and becomes exercisable with respect to escalating portions of the option grant upon the Issuer's stock price reaching certain pre-established levels ranging from $4.50 to $9.00 per share, subject to the Reporting Person's continued service to the Issuer through the vesting date.